News
HCM
13.40
-2.69%
-0.37
HUTCHMED's Fanregratinib Receives Priority Review In China For FGFR2 Cholangiocarcinoma- Update
NASDAQ · 17h ago
Hutchmed's NDA For Fanregratinib In Intrahepatic Cholangiocarcinoma Accepted In China
NASDAQ · 19h ago
Weekly Report: what happened at HCM last week (1222-1226)?
Weekly Report · 19h ago
Hutchmed announces fanregratinib NDA acceptance in China with priority review
TipRanks · 19h ago
HUTCHMED Announces China NDA Acceptance And Priority Review For Fanregratinib Supported By Phase II Registration Trial Results
Benzinga · 20h ago
HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR FANREGRATINIB IN SECOND-LINE INTRAHEPATIC CHOLANGIOCARCINOMA
Reuters · 20h ago
Weekly Report: what happened at HCM last week (1215-1219)?
Weekly Report · 12/22 10:05
Reported Earlier, HUTCHMED Begins First-In-Human Global Clinical Program For ATTC Candidate HMPL-A251 In Solid Tumors
Benzinga · 12/17 07:09
HUTCHMED Launches Global Phase I Trial of Novel ATTC Drug HMPL-A251 for Solid Tumors
Reuters · 12/17 00:00
HUTCHMED INITIATES GLOBAL CLINICAL DEVELOPMENT OF ATTC CANDIDATE HMPL-A251 IN PATIENTS WITH SOLID TUMORS
Reuters · 12/17 00:00
RSI Alert: HUTCHMED (HCM) Now Oversold
NASDAQ · 12/15 19:29
Weekly Report: what happened at HCM last week (1208-1212)?
Weekly Report · 12/15 10:11
Bank of America Securities Sticks to Their Buy Rating for HUTCHMED (HCM)
TipRanks · 12/09 11:55
Weekly Report: what happened at HCM last week (1201-1205)?
Weekly Report · 12/08 10:10
Hutchmed announces contract renewal with the China NHSA
TipRanks · 12/08 01:50
HUTCHMED ANNOUNCES EXPANDED COVERAGE ON NATIONAL REIMBURSEMENT DRUG LIST AND INCLUSION IN THE FIRST COMMERCIAL INSURANCE DRUG LIST IN CHINA
Reuters · 12/08 00:00
Weekly Report: what happened at HCM last week (1124-1128)?
Weekly Report · 12/01 10:06
HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings
Reuters · 11/27 00:00
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
Barchart · 11/26 18:00
Weekly Report: what happened at HCM last week (1117-1121)?
Weekly Report · 11/24 10:10
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.